# AI Venture Spec

## Name:
**RheumatologyAI - Rheumatology Prior Auth & Infusion Platform**

## Core Concept:
AI-powered platform for rheumatologists that automates biologic prior authorization, step therapy navigation, infusion billing, and rheumatoid arthritis treatment documentation.

## Problem:
- **5,000+ rheumatologists** in US
- **Biologics = $5K-$50K annually**: Humira, Enbrel, Remicade, etc.
- **Prior authorization burden**: 80%+ of biologic prescriptions require prior auth
- **Step therapy**: Fail-first protocols delay treatment (disease progression)
- **Infusion billing**: J-code billing for Remicade, Actemra, etc.
- **Rheumatoid arthritis**: Chronic disease = lifelong treatment = ongoing prior auth burden

## Target Vertical:
**Primary:** Rheumatology Practices
- Rheumatology specialists
- Infusion centers (rheumatology-focused)
- Hospital-based rheumatology departments
- Rheumatology research centers

**Secondary:** Infusion pharmacies, biologic manufacturers, rheumatology patients

## Why Now:
1. **Biologic explosion**: New biologics (Humira biosimilars, Rinvoq, etc.) = more prior auth
2. **Step therapy crisis**: Insurers requiring fail-first (methotrexate failure before biologic)
3. **Infusion growth**: Infusion centers growing (site of care shift from hospital to clinic)
4. **Biosimilars**: Humira biosimilars (2023) = prior auth complexity
5. **Chronic disease**: RA, psoriatic arthritis, ankylosing spondylitis = lifelong treatment

## AI Advantage:
- **Biologic prior auth automation**: AI completes prior auth (rheumatology guidelines, ACR criteria)
- **Step therapy navigation**: AI identifies step therapy exceptions, generates appeals
- **Infusion billing optimization**: AI maximizes J-code billing, minimizes waste
- **Disease activity scoring**: AI calculates DAS28, CDAI (rheumatoid arthritis severity)
- **Biosimilar substitution**: AI identifies cheaper biosimilars (Humira → Amjevita)
- **Prior auth renewal**: Auto-renews prior auth (biologics require ongoing approval)

## Viral Mechanism:
- **ACR conferences**: American College of Rheumatology annual meeting
- **Rheumatology community**: Specialized, word-of-mouth
- **Infusion center networks**: Sharing best practices
- **Case studies**: "Got biologic approved 50% faster using AI"
- **Patient advocacy**: Arthritis Foundation, patient groups

## Revenue Model:
**Per-Practice Subscription:**
- **Solo**: $1,000/month - 1-3 rheumatologists, prior auth automation
- **Practice**: $2,500/month - 4+ rheumatologists, infusion billing + step therapy
- **Enterprise**: $6,000/month - Multi-location + white-label + EMR integration

**Per-Prior-Auth add-on:**
- $50 per complex prior auth (beyond included tiers)

**Implementation:**
- $5,000 one-time (payer rule setup, infusion billing setup, training)

**Unit Economics:**
- CAC: $150 (ACR conferences, rheumatology partnerships)
- LTV: $54,000 (36-month retention - switching costs high)
- Gross Margin: 82%

## Moat:
1. **Rheumatology expertise**: Biologics, step therapy, infusion protocols, disease activity scores
2. **Payer rules**: Each payer has different biologic prior auth criteria (step therapy protocols)
3. **ACR guidelines**: American College of Rheumatology treatment guidelines
4. **Infusion billing**: J-code billing, drug waste, prior auth for infusion
5. **Biosimilars**: Humira biosimilars = substitution rules, prior auth

## MVP in 12 Weeks:
**Weeks 1-3:**
- Focus: Top 5 biologics only (Humira, Enbrel, Remicade, Cosentyx, Rinvoq)
- ONE payer (UnitedHealthcare)
- Manual workflow

**Weeks 4-6:**
- Build AI biologic prior auth completer (UHC criteria)
- Step therapy exception identifier
- DAS28 calculator (disease activity)

**Weeks 7-9:**
- Partner with 3 rheumatology practices
- Deploy pilot for top 5 biologics + UHC
- Validate: Prior auth approval rate, time to treatment

**Weeks 10-12:**
- Add 5 more payers (Aetna, Cigna, Humana, BCBS, Medicare)
- Infusion billing module
- Prepare ACR conference demo

**Validation Metrics:**
- 70%+ prior auth approval rate (vs. 50-60% baseline)
- 60%+ reduction in prior auth time
- 2+ practices commit after pilot
- One step therapy exception granted using AI appeal

## Tech Stack:
- **Backend**: Python/FastAPI
- **AI**: GPT-4 (prior auth completion, appeal letters), Custom ML (payer rule tracking)
- **Integrations**: Rheumatology EMRs, payer portals, infusion management systems
- **Infrastructure**: AWS (US regions, HIPAA compliant)

## Monthly Revenue Potential (Year 1–3):
- **Year 1**: $12K MRR (12 practices × $1K ARPU)
- **Year 2**: $60K MRR (60 practices + practice tier)
- **Year 3**: $180K MRR (180 practices + enterprise)

## Risk Factors:
1. **Payer rules**: Biologic prior auth criteria change frequently
2. **Biosimilar competition**: Biosimilars = cheaper, but prior auth still required
3. **Step therapy**: Insurers tightening fail-first requirements
4. **Competition**: Prior auth platforms (SamaCare expanding, CoverMyMeds)
5. **Specialty pharmacies**: Specialty pharmacies may add prior auth services

## Competitive Threat:
- **OncologyPriorAuthAI**: Similar model (oncology prior auth) - potential expansion
- **SamaCare**: Prior auth platform (oncology focus, could expand)
- **CoverMyMeds**: General prior auth (not specialty-focused)
- **Infusion software**: Intrivo, Trimedx (infusion management, not prior auth)

**Differentiation**: Only AI platform for rheumatology with biologic prior auth, step therapy navigation, and infusion billing.

---

## Agent Evaluation Summary

**Score: 8.2/10 - PURSUE** ⭐

**Strengths:**
- **5,000+ rheumatologists**: Specialized market
- **High-cost biologics**: $5K-$50K annually = prior auth burden
- **Prior authorization explosion**: 80%+ require prior auth
- **Step therapy pain**: Fail-first = delay (disease progression)
- **Chronic disease**: Lifelong treatment = ongoing prior auth
- **ACR guidelines**: Standardized treatment criteria

**Weaknesses:**
- Payer rules change frequently
- Competition exists (SamaCare, oncology prior auth)
- Biosimilars = price pressure

**Why this scores 8.2:**
- **$5K-$50K biologics** = high stakes
- **80% prior auth rate** = massive pain
- **Step therapy** = delay = disease progression
- **Chronic disease** = lifelong treatment
- **Specialized** = rheumatology-specific

**Strong rheumatology opportunity.**

## Go/No-Go Decision: **GO** ✅

**Critical success factors:**
1. Hire rheumatologists/rheumatology practice managers as co-founders/advisors
2. Start with top 5 biologics (Humira, Enbrel, Remicade, Cosentyx, Rinvoq)
3. Partner with ACR for distribution
4. Build step therapy exception module (key differentiator)
5. Add infusion billing module (revenue optimization)

**Excellent rheumatology prior authorization opportunity.**
